; The Yale Diabetes Research Center (DRC) was established in 1993 with the goal of promoting research in diabetes and related metabolic and endocrine disorders at the University. The DRC brings together a multidisciplinary group of over 100 member and associate member scientists as well as professional supporting staff, new Investigators and research trainees from in 16 departments and 4 colleges or schools at Yale University The scope ofthe research activities ofthe membership is very broad, ranging from basic molecular biology to whole body physiology and the treatment of diabetic patients. The members, however, share a common interest in research that is related to diabetes and metabolism or is fundamental to understanding its pathogenesis or for the development of new treatment strategies. The design of the Yale DRC is aimed at developing an Infrastructure that could serve as a catalyst to stimulate innovative diabetes-related research. The cornerstone of the DRC is its five Research Cores that provide funded basic and clinical investigators with the opportunity to more efficiently utilize resources and expand the scope of their research programs. The Clinical Metabolism and the Diabetes Translational Cores facilitate metabolic research in patients, whereas the Molecular Genetic Mouse Core, Physiology and Cell Biology Cores that comprise the more basic science focus of the Center offer investigators the tools to create and test novel animal models starting from the molecule and ending with biological outcomes. The Administrative Core oversees the operation ofthe Center, Its Pilot/Feasibility Project and Enrichment Programs, and helps to coordinate patient-based research in diabetes. The goals ofthe DRC are to: 1) stimulate multldisciplinary Interactions, particularly between basic and clinical scientists;2) encourage established Investigators not presently working in diabetes-related areas, to bring their expertise to bear on problems relevant to diabetes;3) efficiently organize time consuming and/or costly techniques through Core facilities to enhance the productivity of investigators conducting research in diabetes related areas;4) promote new research programs through pilot feasibility projects;5) enhance the quality of research training, and 6) create a stimulating institutional environment that enhances research efforts by its members to develop new strategies to prevent and treat diabetes and related metabolic disorders at the local and national level.
; The Yale Diabetes Research Center provides the infrastructure to support a wide spectrum clinical and basic scientists who are working collaboratively to understand why diabetes develops, and to translate discoveries from the bench to the bedside and ultimately to new strategies for the prevention and treatment of patients with, or who are at risk for developing diabetes.
|Perry, Rachel J; Samuel, Varman T; Petersen, Kitt F et al. (2014) The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510:84-91|
|Madiraju, Anila K; Erion, Derek M; Rahimi, Yasmeen et al. (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542-6|
|Sajan, Mini P; Ivey 3rd, Robert A; Lee, Mackenzie et al. (2014) PKC? haploinsufficiency prevents diabetes by a mechanism involving alterations in hepatic enzymes. Mol Endocrinol 28:1097-107|
|Cantley, Jennifer L; Vatner, Daniel F; Galbo, Thomas et al. (2014) Targeting steroid receptor coactivator 1 with antisense oligonucleotides increases insulin-stimulated skeletal muscle glucose uptake in chow-fed and high-fat-fed male rats. Am J Physiol Endocrinol Metab 307:E773-83|
|Birkenfeld, Andreas L; Shulman, Gerald I (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59:713-23|
|Church, Christopher D; Berry, Ryan; Rodeheffer, Matthew S (2014) Isolation and study of adipocyte precursors. Methods Enzymol 537:31-46|
|Liang Liang; Hongying Shen; De Camilli, Pietro et al. (2014) A novel multiple hypothesis based particle tracking method for clathrin mediated endocytosis analysis using fluorescence microscopy. IEEE Trans Image Process 23:1844-57|
|Tooley, James E; Herold, Kevan C (2014) Biomarkers in type 1 diabetes: application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes 21:287-92|
|Sherr, Jennifer L; Ghazi, Tara; Wurtz, Anna et al. (2014) Characterization of residual * cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev 30:154-62|
|Berry, Ryan; Church, Christopher D; Gericke, Martin T et al. (2014) Imaging of adipose tissue. Methods Enzymol 537:47-73|
Showing the most recent 10 out of 337 publications